ARCHIVES

Phase II Study Of Pfizer Drug Meets Primary Endpoint

This article is from The Cancer Letter archive.

Vol. 32 No. 4 | April 24, 2009

Download PDF Visit The Full Archive

Related Articles

Funding Opportunities (8-page issue).

May 23, 2003

Appreciation: Quack-Buster Saul Green Used Science to Debunk Alternative Medicine Claims.

July 13, 2007

DCPC Advisors Approve Five New RFA concepts, Set Aside $33.6 Million

June 4, 1993

Survival Of Control Programs After NCI Money Runs Out Developing Into A Worrisome Issue

June 1, 1975

ODAC Nixes Abraxane for Adjuvant Breast Cancer, While Genasense Falls Victim to Its Randomized Trial.

September 8, 2006

Funding Opportunity: PanCAN Offering $4.1 Million in Research Grants

September 12, 2014